The scrutiny follows a July 27, 2026, announcement where the company revealed that its schizophrenia treatment failed to meet statistical significance on its primary endpoint. Although the 330/6 mg once-daily dose showed numerical improvement over a placebo, the results fell short of the benchmarks required for regulatory confidence. Investors reacted sharply to the data, driving shares down by more than half in premarket trading before the market opened to a 65% loss.
Shareholders Weigh Legal Action Against MapLight Therapeutics
A 65% single-day collapse in MapLight Therapeutics stock has triggered a formal investigation by Schall, Brown & Schwartz LLP. The firm is currently reviewing whether the company misled investors or suppressed critical information regarding the efficacy of its primary schizophrenia drug candidate during recent clinical trials.
Schall, Brown & Schwartz LLP is now soliciting contact from shareholders who suffered financial losses following the disclosure. Partners Brian Schall and David Schwartz are leading the inquiry from their Los Angeles office, aiming to determine if the company’s prior statements regarding the drug's development trajectory were accurate or if they obscured potential risks. The firm specializes in securities litigation and is evaluating the viability of a class action suit to recover damages for those affected by the sudden devaluation.
Comments (0)
No comments yet. Be the first!